-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Rivus Pharmaceuticals announced that its investigational therapy HU6 has achieved positive results in a Phase 2a clinical trial
HU6 is a type of Controlled Metabolic Accelerators (CMAs), an innovative approach to limited activation of mitochondrial uncoupling, a natural process by which the body regulates and consumes energy
This randomized, double-blind, placebo-controlled Phase 2a clinical trial of 80 patients evaluated three different doses of HU6 in obese subjects (BMI 28-42) with high liver fat levels (greater than 8%) safety and efficacy
At 8 weeks, in the absence of changes in participants' dietary and exercise behaviors, weight loss was almost entirely due to fat loss and skeletal muscle mass remained unchanged
Subjects in the high-dose group lost an average of 6 pounds compared to placebo, and subjects with elevated HbA1c levels lost more weight and fat, losing an average of 10 pounds (p<0.
Key cardiovascular and metabolic health markers, including HbA1c levels, high-sensitivity C-reactive protein (hsCRP, an important parameter of cardiovascular risk) decreased in a dose-dependent manner
HU6 was well tolerated at all dose levels with excellent compliance
References:
[1] Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants.
(Original abridged)
